Annovis Bio, Inc. (ANVS) Key Metrics
ANVS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $42.4M
- Enterprise value
- $35.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 25.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.23
ANVS key metrics, 2012–2025
Fiscal year ended December 31, 2025 · U.S. dollarsANVS valuation Price multiples at each fiscal year-end price.
Price / book−36.2%
4.2
2025 · hover or tap a bar for each year
20122025
Free cash flow yield−0.5 pts
−36.0%
2025 · hover or tap a bar for each year
20122025
ANVS returns How much profit the business earns on the capital it uses.
Return on equity
−220.6%
2025 · hover or tap a bar for each year
20122025
Return on assets+38.9 pts
−164.8%
2025 · hover or tap a bar for each year
20122025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20122025
ANVS per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20122025
Earnings per share
−$1.40
2025 · hover or tap a bar for each year
20122025
Free cash flow per share
−$1.25
2025 · hover or tap a bar for each year
20122025
Book value per share+7.8%
$0.82
2025 · hover or tap a bar for each year
20122025
Shares outstanding+68.0%
20.6M
2025 · hover or tap a bar for each year
20122025
ANVS financial health Debt, liquidity and how easily interest is covered.
Net debt−$9.0M
−$19.5M
2025 · hover or tap a bar for each year
20122025
Current ratio+61.6%
5.80
2025 · hover or tap a bar for each year
20122025
ANVS valuation history
Fiscal year-endToday10-year median
ANVS returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ANVS debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ANVS price vs earnings per share
Share price at year-endEPS (right axis)
ANVS key metrics
2012–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $71.1M | $61.5M | $168.7M | — | — | — | — | — | — | — |
| Enterprise value | $51.6M | $51.0M | $163.0M | — | — | — | — | — | — | — |
| Price / book | 4.2 | 6.6 | — | — | — | — | — | — | — | — |
| Earnings yield | −40.6% | −40.0% | −33.3% | — | — | — | — | — | — | — |
| Free cash flow yield | −36.0% | −35.6% | −23.7% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $3.46 | $5.03 | $18.70 | $13.43 | $17.58 | $7.54 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Earnings per share | −$1.40 | −$2.01 | −$6.23 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.25 | −$1.79 | −$4.43 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.25 | −$1.79 | −$4.43 | — | — | — | — | — | — | — |
| Cash per share | $0.95 | $0.86 | $0.64 | — | — | — | — | — | — | — |
| Book value per share | $0.82 | $0.76 | −$0.86 | — | — | — | — | — | — | — |
| Tangible book value per share | $0.82 | $0.76 | −$0.86 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Shares outstanding | 20.6M | 12.2M | 9.0M | — | — | — | — | — | — | — |
| Change in shares outstanding | +68.0% | +35.6% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −220.6% | — | — | −69.1% | −55.7% | — | — | — | — | −100.4% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | — | −18.5% |
| Return on assets (ROA) | −164.8% | −203.8% | −243.1% | −61.3% | −53.5% | −118.3% | −169.7% | −349.1% | −42.7% | −69.8% |
| Return on tangible assets | −136.9% | −176.6% | −550.6% | −69.8% | −31.5% | −67.3% | −88.7% | — | −190.6% | −502.1% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −805.9% |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | — | $499,807 | — | — | — |
| Cash & short-term investments | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1,858 | $35,312 | $347,472 | $72,316 |
| Net debt | −$19.5M | −$10.6M | −$5.8M | −$28.4M | −$45.7M | −$8.1M | $497,949 | −$35,312 | −$347,472 | −$72,316 |
| Debt / assets | — | — | — | — | — | — | 0.45 | — | — | — |
| Current ratio | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | 0.09 | 0.73 | 9.14 |
| Quick ratio | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 371.20 | 0.09 | 0.73 | 9.01 |
| Interest coverage | — | -14.4 | — | -139.6 | — | -0.1 | -0.0 | — | — | — |
| Working capital | $17.4M | $10.0M | $5.9M | $28.3M | $44.5M | $7.5M | −$1.3M | −$516,951 | −$132,257 | $1.4M |
| Invested capital | −$2.7M | −$1.2M | −$13.5M | −$54,163 | −$1.2M | −$533,704 | −$8.1M | −$7.6M | −$7.3M | $2.6M |
| Tangible asset value | $16.9M | $9.3M | −$7.8M | $28.3M | $44.5M | $7.5M | −$8.6M | −$7.6M | −$7.0M | $1.5M |
| Net current asset value | $16.9M | $9.3M | −$7.8M | $28.3M | $44.5M | $7.5M | −$8.9M | −$7.6M | −$7.0M | $1.4M |
| Graham net-net per share | $0.74 | $0.48 | −$1.35 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | $0 | $0 | — | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | — | — | 43.0% |
| Capex / depreciation | — | — | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.39 |
| SG&A / revenue | — | — | — | — | — | — | — | — | — | 1,051.9% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | — | 6,429.4 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | — | 84,072.3 |
| Days payables outstanding | — | — | — | — | — | — | — | — | — | 114,124.0 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | — | -23,622.4 |
| Receivables turnover | — | — | — | — | — | — | 0.00 | — | — | 0.06 |
| Payables turnover | — | — | — | — | — | — | — | — | — | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Average receivables | — | — | — | — | — | — | $735,075 | — | — | $3.3M |
| Average payables | $2.4M | $1.8M | $2.6M | $2.3M | $514,965 | $787,866 | $651,151 | $69,766 | $122,735 | $3.6M |
| Average inventory | — | — | — | — | — | — | −$745.6M | — | — | $2.6M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 41.5% |
Computed from ANVS's annual financial statements (latest annual report filed March 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ANVS valuation and financial ratios
Annovis Bio earned a return on equity of −220.6% in fiscal 2025.
See the ANVS income statement, the ANVS chart for price history, or the ANVS stock overview for the latest quote and news.
ANVS key metrics FAQ
What is Annovis Bio's return on equity?
Annovis Bio's return on equity (ROE) was −220.6% in fiscal 2025: net income of -$28.9 million on average shareholders' equity of $13.1 million.
What is Annovis Bio's free cash flow yield?
Annovis Bio generated -$25.6 million of free cash flow in fiscal 2025, a free cash flow yield of −36.0% on its market value at year-end ($71.1 million).
What is Annovis Bio's current ratio?
Annovis Bio's current ratio was 5.80 at the end of fiscal 2025: current assets were 5.80 times current liabilities.